Neogen shares soar 12% as first quarter results top expectations

Published 09/10/2025, 12:12
 Neogen shares soar 12% as first quarter results top expectations

LANSING, Mich. - On Thursday, Neogen Corporation (NASDAQ:NEOG) reported first-quarter results that exceeded analyst expectations, despite ongoing challenges in its business operations.

The food and animal safety company’s shares surged 12.20% in pre-market trading after the results.

The company posted adjusted earnings of $0.04 per share for the quarter ended August 31, significantly beating the analyst consensus estimate of -$0.07. Revenue came in at $209.2 million, surpassing the expected $202.43 million, though it represented a 3.6% decrease from $217 million in the same period last year.

Core revenue, which excludes the impacts of foreign currency translation and divestitures, increased by a modest 0.3%. The company’s gross margin fell to 45.4% from 48.4% a year ago, primarily due to integration-related costs associated with relocated production of sample collection products.

"I see tremendous opportunity ahead to leverage Neogen’s strong, longstanding leadership in food and animal safety," said Mike Nassif, Neogen’s newly appointed CEO and President. "Recent performance has been hampered by execution challenges which we are tackling head-on with a sharpened emphasis on commercial excellence, renewed innovation and a leaner cost structure."

The company recently implemented cost-cutting initiatives, including workforce reductions, to improve margins and enable strategic reinvestment. During the quarter, Neogen completed the divestiture of its Cleaners & Disinfectants business and used the proceeds to repay $100 million of debt.

Neogen reaffirmed its full-year outlook, projecting revenue between $820 million and $840 million, above the consensus estimate of $819.1 million. Adjusted EBITDA is expected to range from $165 million to $175 million.

The company’s Food Safety segment saw a 4.6% revenue decline to $152.1 million, while Animal Safety revenue decreased 0.8% to $57.1 million. On a positive note, Neogen’s Genomics business returned to positive core revenue growth in the mid-single-digit range.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.